Zimmer Biomet Holdings Inc
$ 96.55
-0.66%
07 Aug - close price
- Market Cap 18,537,798,000 USD
- Current Price $ 96.55
- High / Low $ 96.89 / 94.88
- Stock P/E 23.82
- Book Value 65.73
- EPS 4.08
- Next Earning Report -
- Dividend Per Share $0.48
- Dividend Yield 0.49 %
- Next Dividend Date -
- ROA 0.04 %
- ROE 0.06 %
- 52 Week High 107.16
- 52 Week Low 78.91
About
Zimmer Biomet is a publicly traded medical device company. The company is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.
Analyst Target Price
$106.76
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-04-28 | 2026-02-10 | 2025-11-05 | 2025-08-07 | 2025-05-05 | 2025-02-06 | 2024-10-30 | 2024-08-07 | 2024-05-02 | 2024-02-08 | 2023-11-07 |
| Reported EPS | 2.07 | 2.09 | 2.42 | 1.9 | 2.07 | 1.81 | 2.31 | 1.74 | 2.01 | 1.94 | 2.2 | 1.65 |
| Estimated EPS | 2.01 | 1.86 | 2.4 | 1.88 | 1.98 | 1.77 | 2.29 | 1.74 | 1.99 | 1.87 | 2.16 | 1.6 |
| Surprise | 0.06 | 0.23 | 0.02 | 0.02 | 0.09 | 0.04 | 0.02 | 0 | 0.02 | 0.07 | 0.04 | 0.05 |
| Surprise Percentage | 2.9851% | 12.3656% | 0.8333% | 1.0638% | 4.5455% | 2.2599% | 0.8734% | 0% | 1.005% | 3.7433% | 1.8519% | 3.125% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-07-31 | 2026-04-30 | 2026-01-30 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 |
| Amount | $0.24 | $0.24 | $0.24 | $0.24 | $0.24 | $0.24 | $0.24 | $0.24 | $0.24 | $0.24 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ZBH
2026-08-07 11:39:21
Wells Fargo has increased its price target for Zimmer Biomet Holdings Inc. (ZBH) to $103, up from the previous $90. The firm maintained an Equal-Weight rating on the stock. This adjustment reflects a revised outlook on the company's financial performance.
2026-08-07 11:15:28
Wilsey Asset Management Inc. increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.7% in the second quarter, bringing its total holdings to 421,867 shares valued at $36.32 million. The medical equipment provider recently reported strong Q2 earnings, beating analyst estimates with $2.18 billion in revenue and $2.07 adjusted EPS, and maintained its 2026 adjusted EPS guidance. Despite mixed analyst sentiment and some margin pressure, the company also announced a quarterly dividend of $0.24 per share, translating to a 1.0% annualized yield.
2026-08-07 10:09:56
Truist has increased its price target for Zimmer Biomet Holdings, Inc. (ZBH) to $106 from $92, while reiterating a Hold rating on the stock. This adjustment reflects an updated outlook from the analyst firm. Several other financial institutions have also recently revised their price targets for Zimmer Biomet, with some maintaining or adjusting their ratings.
2026-08-07 08:10:28
Cerus Corp (CERS) has an earnings forecast score of 8.67, ranking 17th in its industry, with an average analyst price target of $5.00, suggesting a 113.09% upside. Based on 3 analysts, the stock is rated as a "Buy." The company's expected revenue for the next quarter is $61.60 million, and its EPS for the previous and next quarters is estimated at -$0.01.
2026-08-07 07:37:02
Align Technology (ALGN) is the leading manufacturer of clear aligners, with its Invisalign product dominating over 90% of the market since its 1998 FDA approval. The company recently reported mixed earnings, where better-than-expected case volume was offset by weak scanner sales. The stock currently trades at $169.78.
2026-08-07 05:14:43
Zimmer Biomet Holdings (ZBH) recently reported stronger-than-expected quarterly results and increased its guidance, driven by solid execution in U.S. hip and technology lines and sales force restructuring progress. Despite a significant 5-year decline in shareholder return, the company's recent 90-day share price return of 18.05% suggests improving momentum as investors re-evaluate its growth prospects. While trading at $97.19 against a fair value estimate of $102.19, the stock is considered partially re-rated and undervalued, with future growth expected from its investment in digital health, robotics, and data-driven surgical solutions.
